(Q36613860)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

16 January 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Stephen J. Walters

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

L Turner

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

B W Hancock

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

1 February 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

492-498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

Adjuvant treatment of malignant melanoma: where are we?

16 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Quality-of-life evaluation in an interferon therapy after radical surgery in cutaneous melanoma patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Training care givers of stroke patients: economic evaluation

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Adjuvant therapy of malignant melanoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Patient preferences for adjuvant interferon alfa-2b treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Adjuvant interferon-alpha in malignant melanoma: current status

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Methods for the analysis of quality-of-life and survival data in health technology assessment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Modeling valuations for EuroQol health states

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Analysis of serial measurements in medical research

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Assessing quality of life in people with multiple sclerosis.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361187

Statistical handling of drop‐outs in longitudinal clinical trials

20 September 2018

1 reference

12 December 2020

Validation of the FACT-BRM with interferon-alpha treated melanoma patients

1 reference

12 December 2020

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma

1 reference

12 December 2020

Cognitive function and quality of life in interferon therapy for melanoma

1 reference

12 December 2020

Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6602973

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16449995%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

PubMed publication ID

16449995

1 reference